Bet Bromodomain Inhibitor Zen-3694
Prostate Adenocarcinoma
Explore 89 assets in Prostate Adenocarcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Rahul Aggarwal
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04471974CT.gov ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bet Bromodomain Inhibitor Zen-3694 (this asset) | Rahul Aggarwal | P2 | CCC · 53 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Prednisone | Mayo Clinic | P3 | BB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Lidocaine | Bagcilar Training and Research Hospital | P4 | BB |
| Leuporelin | Mayo Clinic | P3 | BB |
| Bicalutamide | OHSU Knight Cancer Institute | P3 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for Bet Bromodomain Inhibitor Zen-3694
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Triple-Negative Breast Carcinoma | — | P2 | B · 60 |
| Prostate Cancer | — | P2 | B · 60 |
| Metastatic Prostate Carcinoma | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bet Bromodomain Inhibitor Zen-3694 in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bet-bromodomain-inhibitor-zen-3694-prostate-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →